Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33,874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
Hollander E, Jacob S, Jou R, McNamara N, Sikich L, Tobe R, Smith J, Sanders K, Squassante L, Murtagh L, Gleissl T, Wandel C, Veenstra-VanderWeele J. Hollander E, et al. Among authors: smith j. JAMA Psychiatry. 2022 Aug 1;79(8):760-769. doi: 10.1001/jamapsychiatry.2022.1717. JAMA Psychiatry. 2022. PMID: 35793101 Free PMC article. Clinical Trial.
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-Bhullar G, Wandel C, Ashford E, Anagnostou E. Jacob S, et al. Among authors: smith j. Lancet Psychiatry. 2022 Mar;9(3):199-210. doi: 10.1016/S2215-0366(21)00429-6. Epub 2022 Feb 10. Lancet Psychiatry. 2022. PMID: 35151410 Clinical Trial.
Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.
Jacob S, Anagnostou E, Hollander E, Jou R, McNamara N, Sikich L, Tobe R, Murphy D, McCracken J, Ashford E, Chatham C, Clinch S, Smith J, Sanders K, Murtagh L, Noeldeke J, Veenstra-VanderWeele J. Jacob S, et al. Among authors: smith j. Mol Autism. 2022 Jun 11;13(1):25. doi: 10.1186/s13229-022-00505-6. Mol Autism. 2022. PMID: 35690870 Free PMC article.
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.
Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. Salloway S, et al. Among authors: smith j. JAMA Neurol. 2025 Jan 1;82(1):19-29. doi: 10.1001/jamaneurol.2024.3937. JAMA Neurol. 2025. PMID: 39556389 Free PMC article. Clinical Trial.
Quantitative and Qualitative Exploration of Meaningful Change on the Vineland Adaptive Behavior Scales (Vineland™-II) in Children and Adolescents with Autism Without Intellectual Disability Following Participation in a Clinical Trial.
Clinch S, Hudgens S, Gibbons E, Willgoss T, Smith J, Polek E, Burbridge C. Clinch S, et al. Among authors: smith j. Patient Relat Outcome Meas. 2023 Nov 20;14:337-354. doi: 10.2147/PROM.S385542. eCollection 2023. Patient Relat Outcome Meas. 2023. PMID: 38027418 Free PMC article.
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Neve A, et al. Among authors: smith j. J Alzheimers Dis. 2024;101(1):353-367. doi: 10.3233/JAD-240221. J Alzheimers Dis. 2024. PMID: 39177596 Free PMC article. Clinical Trial.
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Boada M, et al. Among authors: smith j. J Alzheimers Dis. 2024 Dec 16:13872877241303644. doi: 10.1177/13872877241303644. Online ahead of print. J Alzheimers Dis. 2024. PMID: 39686620
Gantenerumab in Early Alzheimer's Disease. Reply.
Bateman RJ, Smith J, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. Among authors: smith j. N Engl J Med. 2024 Feb 29;390(9):867. doi: 10.1056/NEJMc2314291. N Engl J Med. 2024. PMID: 38416440 No abstract available.
33,874 results
You have reached the last available page of results. Please see the User Guide for more information.